Your account is not claimed yet. You can sign up with ORCID to claim your account.

Michael L West

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Topics

Smoking Cessation

Cross Sectional

Atrial Fibrillation

Replacement Therapy

Top Venues

Journal of clinical medicine

Drug design, development and therapy

Dalhousie University

Queen's University (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Dalhousie University Jul 1o 1990

Canada

Professor of Medicine :: Medicine

Education History

Queen's University

Canada

BSC

Publications

Christiane Auray-Blais, Pamela Lavoie, Tristan Martineau, Georges Kabala Ntumba, Mohamed Gamrani, Aneal Khan, Gheona Altarescu, Anna Lehman, Ozlem Goker-Alpan, Albina Nowak, Michael L West, Daniel G Bichet
Fabry disease biomarkers in patients switched from enzyme replacement therapy to migalastat oral chaperone therapy. Bioanalysis (2023)
Markus Cybulla, Kathleen Nicholls, Sandro Feriozzi, Aleš Linhart, Josep María Cruzado, Bojan Vujkovac, Jaco Botha, Christina Anagnostopoulou, Michael L West, null null
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease. Journal of clinical medicine 11 (16) (2022)
Aneal Khan, Sandra M Sirrs, Daniel G Bichet, Chantal F Morel, Adina Tocoian, Lan Lan, Michael L West, null null
The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process. Drugs in R&D 21 (4) (2021)
Uma Ramaswami, Michael Beck, Derralynn Hughes, Christoph Kampmann, Jaco Botha, Guillem Pintos-Morell, Michael L West, Dau-Ming Niu, Kathleen Nicholls, Roberto Giugliani, null null
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis. Drug design, development and therapy 13 (2019)